Amivantamab in Adenoid Cystic Carcinoma

Status Recruiting

Clinical Trial Summary

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Clinical Trial Description

ACC is a rare cancer of salivary glands and other glandular tissue. It is slow growing and is usually treated with surgery and radiation. However, this type of cancer tends to have a high rate of recurrence and metastatic spread, which develops over several years. We hypothesize that amivantamab, a bispecific EGFR and MET inhibitor will be efficacious in ACC. Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05074940
Study type	Interventional
Source	University of Cincinnati
Contact	UCCC Clinical Trials Office
Phone	513-584-7698
Email	cancer@uchealth.com
Status	Recruiting
Phase	Phase 2
Start date	August 5, 2022
Completion date	August 5, 2028

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03729297` - Cabozantinib in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT01969578` - Androgen Deprivation Therapy in Advanced Salivary Gland Cancer	Phase 2
Completed	`NCT01703455` - Activity of Sorafenib in Salivary Gland Cancer	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT05010629` - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma	Phase 2
Suspended	`NCT03781986` - APG-115 in Salivary Gland Cancer Trial	Phase 1/Phase 2
Completed	`NCT03319641` - PSMA-PET Imaging for Advanced ACC/SDC	N/A
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT05483374` - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT03172624` - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Phase 2
Completed	`NCT00509002` - Iressa Study in Patients With Salivary Gland Cancer	Phase 2
Active, not recruiting	`NCT05008237` - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study	Phase 2
Recruiting	`NCT03360890` - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors	Phase 2
Not yet recruiting	`NCT06091878` - Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers
Not yet recruiting	`NCT05898373` - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC	Phase 1/Phase 2
Active, not recruiting	`NCT02069730` - A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes	N/A
Recruiting	`NCT04209660` - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Phase 2
Completed	`NCT01344356` - Stereotactic Body Radiotherapy for Head and Neck Tumors	Phase 4